亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)

杜瓦卢马布 医学 肺炎 放化疗 肺癌 放射治疗 内科学 癌症 免疫疗法 无容量
作者
Go Saito,Yuko Oya,Yoshihiko Taniguchi,Hayato Kawachi,Daichi Fujimoto,Hirotaka Matsumoto,Shunichiro Iwasawa,Hidekazu Suzuki,Takayuki Niitsu,Eisaku Miyauchi,Takashi Yokoi,Toshihide Yokoyama,Takeshi Uenami,Yoshihiko Sakata,Daisuke Arai,Asuka Okada,Kenji Nagata,Shunsuke Teraoka,Masaki Kokubo
出处
期刊:Lung Cancer [Elsevier]
卷期号:161: 86-93 被引量:41
标识
DOI:10.1016/j.lungcan.2021.08.019
摘要

Objectives The incidence of real-world pneumonitis and durvalumab rechallenge during chemoradiotherapy and durvalumab consolidation for non-small cell lung cancer is unknown. Materials and methods We retrospectively evaluated the medical records of 302 consecutive patients diagnosed with non-small cell lung cancer who started chemoradiotherapy between May 2018 and May 2019. Results Median age was 70 (range: 40–87) years. Volume of lung parenchyma that received 20 Gy (V20) exceeded 35% in 2% and mean lung dose exceeded 20 Gy in 1% of patients. Durvalumab consolidation was delivered to 225 patients (75%). Overall, 83% (n = 251), 34% (n = 103), 7% (n = 21), and 1% (n = 4) of the patients developed any grade of pneumonitis, symptomatic pneumonitis, ≥grade 3 pneumonitis, and fatal (grade 5) pneumonitis, respectively. Corticosteroids were administered to 25% of the patients to treat pneumonitis. Multivariate analysis identified the predictive factors for the development of symptomatic pneumonitis: V20 Gy or more ≥ 25% (odds ratio [OR]: 2.37, P = 0.008) and mean lung dose (MLD) ≥ 10 Gy (OR: 1.93, P < 0.0047). Of the 52 patients who received corticosteroids for pneumonitis after durvalumab initiation, 21 were rechallenged with durvalumab. Overall, 81% of patients met the PACIFIC study’s rechallenge criteria and did not experience a severe pneumonitis relapse. Conclusion High V20 and MLD were independent risk factors of symptomatic pneumonitis. More than 80% of the patients who were rechallenged with durvalumab after pneumonitis met the PACIFIC study’s rechallenge criteria. Consequently, severe relapse did not occur. Cooperation between radiation and medical oncologists is important for safe chemoradiotherapy and the safe completion of durvalumab consolidation therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
快乐的C完成签到,获得积分20
4秒前
原野小年完成签到,获得积分10
4秒前
原野小年发布了新的文献求助10
7秒前
科研通AI2S应助原野小年采纳,获得10
19秒前
28秒前
安安完成签到,获得积分10
34秒前
Yana__Chan完成签到 ,获得积分10
34秒前
今后应助科研通管家采纳,获得10
44秒前
niuzyang发布了新的文献求助10
48秒前
Ava应助阿尼亚采纳,获得10
49秒前
49秒前
淡定的半莲完成签到 ,获得积分10
49秒前
老王完成签到 ,获得积分10
53秒前
53秒前
niuzyang完成签到,获得积分20
53秒前
Shrimp完成签到 ,获得积分10
1分钟前
breeze完成签到,获得积分10
1分钟前
葡紫明完成签到 ,获得积分10
1分钟前
蓝鲸完成签到 ,获得积分10
1分钟前
CodeCraft应助哈哈哈哈哈采纳,获得10
1分钟前
压缩完成签到 ,获得积分10
1分钟前
哈哈哈哈哈完成签到,获得积分10
1分钟前
霁昕完成签到 ,获得积分10
1分钟前
乐乐应助fpbovo采纳,获得10
1分钟前
名金学南完成签到,获得积分10
1分钟前
俭朴蜜蜂完成签到 ,获得积分10
1分钟前
1分钟前
Omni完成签到,获得积分10
1分钟前
远方完成签到,获得积分10
1分钟前
云飞扬完成签到 ,获得积分10
1分钟前
Clove完成签到 ,获得积分10
1分钟前
shweah2003完成签到,获得积分10
1分钟前
研友_8y2o0L发布了新的文献求助10
1分钟前
2分钟前
Jasper应助研友_8y2o0L采纳,获得10
2分钟前
2分钟前
2分钟前
2分钟前
sun发布了新的文献求助10
2分钟前
高分求助中
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Handbook of Qualitative Cross-Cultural Research Methods 600
Chen Hansheng: China’s Last Romantic Revolutionary 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 500
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3139490
求助须知:如何正确求助?哪些是违规求助? 2790349
关于积分的说明 7795082
捐赠科研通 2446818
什么是DOI,文献DOI怎么找? 1301448
科研通“疑难数据库(出版商)”最低求助积分说明 626238
版权声明 601146